TenQ

The Tilray Brands story

Tilray Brands combines cannabis, craft beverages and pharmaceutical distribution, with the central question whether BrewDog and international medical cannabis can turn a broader business into sustained profits and cash generation.

Tilray Brands stock reportTenQ Score 9/36 · every chart and check from its filings
  • $3.04share price, last close
  • $449Mmarket value
  • 9/36TenQ Score checks passed

The story in brief

  • Beverages reshape Tilray. In the quarter to August 2026, BrewDog helped beverage revenue rise 82% to $101.5 million, while total revenue increased 23% to $257.1 million.
  • Earnings lag revenue. Adjusted EBITDA fell to $9.2 million from $10.2 million in the quarter to August 2026, despite gross margin expanding to 30% from 27%.
  • Cash cushions losses. Tilray ended the quarter to August 2026 with a reported net cash position and $221.4 million in cash, restricted cash and marketable securities, but recorded a $40.0 million net loss.

What drives the business

  • Tilray’s diversification beyond Canadian cannabis centers on craft beverages, with the BrewDog acquisition in March and April 2026 adding international brewing, hospitality operations and worldwide brand rights.
  • Its exclusive Carlsberg Group agreement begins January 1, 2027, granting rights to produce and distribute Carlsberg, Carlsberg Elephant, 1664 and Kronenbourg 1664 Blanc beers throughout the United States for an initial five-year term.
  • International medical cannabis relies on cultivation in Canada, Portugal and Germany, pharmaceutical distribution through CC Pharma, and the Lyphe clinic and digital pharmacy acquired in April 2026.
  • In the quarter to August 2026, beverage gross margin reached 41%, while revenue across Europe, the Middle East and Africa increased 71%, led by medical cannabis, beverages and pharmaceutical distribution.
  • Pharmaceutical distribution generated $84.3 million in revenue in the quarter to August 2026, up 14%, while wellness, including Manitoba Harvest hemp foods, generated $15.3 million.

What the price assumes

At $3.59, the reverse DCF cannot measure an implied growth rate because free cash flow and operating earnings are negative, leaving the price dependent on future profits.

The price to sales ratio of 0.6x is below the TenQ sales valuation check’s 2.5x threshold, but that comparison does not establish a cash earnings foundation.

Revenue grew 15.9% over the last twelve months, faster than its three-year annual pace of 13.4% but below the TenQ sector growth bar of 20.4%.

What could change the story

  • BrewDog and other beverage acquisitions bring integration costs and operational disruption risks, so added revenue may not translate into sustained profitability.
  • Cannabis revenue fell to $56.1 million from $64.5 million in the quarter to August 2026, while competition from illicit operators and well-capitalized businesses could pressure revenue and margins.
  • Operations depend on licenses and regulatory approvals across jurisdictions, and legal challenges surrounding broader U.S. cannabis rescheduling leave that expansion path uncertain.
  • An operating margin of -9.3% and operating cash conversion of -8.8% over the last twelve months explain why liquidity alone does not resolve Tilray’s failing profitability and cash generation checks.
  • Weighted average common shares increased 26% from the prior-year period in the quarter to August 2026 on a split-adjusted basis, showing dilution despite the earlier reverse stock split.

What to watch next

  • Tilray reaffirmed fiscal year 2027 adjusted EBITDA guidance of $68 million to $75 million, with management expecting results to be weighted toward the second half and strengthen significantly in the fourth quarter.
  • Subsequent releases will show whether beverage gross margin holds near 41% and whether cannabis revenue stabilizes after the decline in the quarter to August 2026.
  • Operating cash flow and net income will test whether adjusted EBITDA progress reaches the financial statements, since guidance excludes stock-based compensation, integration costs and other items.
  • The Carlsberg agreement’s January 1, 2027 commencement adds a concrete milestone for assessing utilization of Tilray’s U.S. brewing and distribution network.

Sources

Back to the TLRY report